In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Inc.

Division of Novo Nordisk AS
www.novonordisk-us.com

Latest From Novo Nordisk Inc.

Pediatric Exclusivity For ‘Deemed’ Biologics Needs Clarity, Industry Tells US FDA

Draft guidance says unexpired pediatric exclusivity would continue to apply to a deemed 351(a) BLA on March 23, 2020, but industry says differences in how pediatric exclusivity operates under the statutory frameworks governing drugs and biologics could result in the loss of some marketing protection.

Biosimilars Biologics

Hemophilia Community Not 'Choosing A Side' In Hemlibra Litigation

Shire explains why it is seeking preliminary injunction against Genentech; National Hemophilia Foundation and Hemophilia Federation of America decline to take position on dispute.

BioPharmaceutical Policy

Why Industry Wants ICH To Harmonize Process Validation Guidance

After a proposal for harmonized process validation guidance didn't make the cut at ICH, PhRMA and US FDA proponents are making the case to a broader audience. Current ICH guidance is unclear, and regional guidance is conflicting, they told the ISPE annual meeting.

Manufacturing Quality

Market Intel: Artificial Intelligence Brings Wave Of Future Health Care Innovation – Embrace it or be Left Behind

Artificial intelligence and machine-learning will be the biggest disrupters in the health care industry, forcing a major shift in how companies innovate and operate, offering physicians unprecedented tools to diagnose and treat patients to improve outcomes and connecting patients like never before through consumer-driven devices. This feature takes a close look at how smaller companies and giants like Abbott, as well as national health care systems, are leveraging the power of AI to expedite innovation and product development in diabetes and other diseases. It highlights some of the latest studies that show how AI is being harnessed to improve imaging analytics, predict hard-to-find risk factors for heart disease and detect cancer, and discusses the critical role tech giants such as IBM, Google and Amazon continue to play in this space.

Artificial Intelligence Digital Health
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Novo Nordisk Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novo Nordisk AS
  • Senior Management
  • Jerzy Gruhn, Pres.
    Phil Fornecker, VP, Strategic Bus. Ops.
    Alan Moses, Corp. VP, Global CMO
  • Contact Info
  • Novo Nordisk Inc.
    Phone: (609) 987-5800
    100 College Rd. West
    Princeton, NJ 08540
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register